Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Several factual elements (ingredients, indication, general corticosteroid/antihistamine characterization, and common adverse effects like epistaxis and altered taste/nasal discomfort) are broadly consistent with the provided label excerpts, but multiple claims are unsupported or go beyond the provided label text (FDA approval/safety-efficacy interpretation, GMP oversight, and mechanistic descriptions of how the drugs work).
Category Scores
Accurate Statements
Dymista nasal spray is a prescription nasal spray used for the relief of nasal allergy symptoms.
Indications: “DYMISTA is indicated for the relief of symptoms of seasonal allergic rhinitis in adult and pediatric patients 6 years of age and older.”
Dymista is a combination product containing fluticasone propionate and azelastine hydrochloride.
Drug contains both azelastine and fluticasone: “DYMISTA contains both azelastine hydrochloride and fluticasone propionate...” and dosage forms/strengths list both actives per spray.
Fluticasone propionate in Dymista is a corticosteroid.
Warnings/precautions refer to “corticosteroids” and specifically “fluticasone propionate exposure”; label context treats fluticasone propionate as a nasal corticosteroid.
Azelastine hydrochloride in Dymista is an antihistamine.
Label excerpts provided do not explicitly call azelastine an antihistamine; however, the label characterizes it as part of DYMISTA and discusses allergy indication. (No direct explicit support in provided excerpts.)
Common side effects associated with Dymista include nosebleeds.
Warnings/precautions: “epistaxis was observed more frequently... than... placebo.”
Common side effects associated with Dymista include altered taste.
Provided label excerpts include adverse reaction reporting but do not explicitly list “altered taste.” (No explicit support in the provided excerpts.)
Common side effects associated with Dymista include nasal discomfort.
Provided label excerpts include adverse reaction reporting but do not explicitly list “nasal discomfort.” (No explicit support in the provided excerpts.)
Unsupported Statements
Dymista has received FDA approval for marketing in the United States.
The provided label excerpts do not explicitly state that DYMISTA has received FDA approval.
FDA approval indicates that the drug met FDA standards for safety and efficacy for its intended use.
The provided label excerpts do not make this interpretive statement.
Manufacturing processes and facilities are subject to ongoing FDA oversight to ensure compliance with Good Manufacturing Practices (GMP).
The provided label excerpts do not discuss GMP or FDA manufacturing oversight.
Azelastine hydrochloride in Dymista is an antihistamine.
The provided label excerpts do not explicitly state azelastine is an antihistamine.
Corticosteroid nasal sprays like Flonase (fluticasone propionate) primarily reduce inflammation.
The provided label excerpts do not include this mechanistic/comparative statement.
Antihistamine nasal sprays like Astelin (azelastine hydrochloride) block the action of histamine.
The provided label excerpts do not include this mechanistic statement.
Dymista aims to provide broader and faster symptom relief by addressing both inflammation and histamine-mediated symptoms.
The provided label excerpts do not explicitly describe the intended mechanism/goal as “broader and faster” or “histamine-mediated” symptom relief.
As of now, specific information regarding the launch of generic Dymista in 2025 is not publicly available.
The provided label excerpts do not discuss generic availability or future launch timing.
Contradictions
Important Omissions
The AI response did not include the labeled recommended dosing regimen (1 spray in each nostril twice daily) and administration/priming and reprime instructions.
Importance:
Moderate
The AI response did not mention labeled contraindications (hypersensitivity to azelastine/fluticasone/other ingredients).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Some safety-relevant content (e.g., epistaxis) aligns with the label excerpts, but multiple mechanistic and regulatory/GMP claims are unsupported by the provided label text; additionally, omission of dosing/administration and contraindications could reduce label-accuracy for safe use descriptions.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Several claims are unsupported by the provided label excerpts, particularly regulatory/GMP assertions and mechanistic explanations; also key labeled use details (dosing/administration and contraindications) were omitted.
Suggested Improvement
Limit claims to text directly supported by the provided label excerpts (indication, actives/strengths, labeled epistaxis, labeled precautions/interactions). If describing use, add labeled dosing (1 spray each nostril twice daily) and administration steps (prime/reprime, nasal route only, avoid eye exposure). Avoid interpretive or mechanistic statements not present in the supplied label text.